HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.
This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout
Raymond James downgraded PolyPid Ltd (NASDAQ:PYPD) from Strong Buy to Outperform post SHIELD I Phase 3 results that, despite consistency and evidence of…